An IoT and fog computing-based monitoring system for cardiovascular patients with automatic ECG classification using deep neural networks
Telemedicine and all types of monitoring systems have proven to be a useful and low-cost
tool with a high level of applicability in cardiology. The objective of this work is to present an …
tool with a high level of applicability in cardiology. The objective of this work is to present an …
Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists
C Rebordosa, DK Farkas, J Montonen… - … and Drug Safety, 2022 - Wiley Online Library
Purpose We examined the effect of olodaterol on the risk of myocardial ischaemia, cardiac
arrhythmia, and all‐cause mortality compared with use of other long‐acting beta2‐agonists …
arrhythmia, and all‐cause mortality compared with use of other long‐acting beta2‐agonists …
Absence of adverse effects of tiotropium/olodaterol compared with the monocomponents on long-term heart rate and blood pressure in patients with moderate-to-very …
S Andreas, L McGarvey, U Bothner… - … journal of chronic …, 2020 - Taylor & Francis
Introduction Long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists
(LAMAs) are established maintenance bronchodilator treatments for chronic obstructive …
(LAMAs) are established maintenance bronchodilator treatments for chronic obstructive …
Effects of LAMA/LABA alone and in combination on cardiac safety
S Andreas - … Journal of Chronic Obstructive Pulmonary Disease, 2020 - Taylor & Francis
Chronic obstructive pulmonary disease (COPD) is a multidimensional, progressive condition
characterized by airflow obstruction, worsening dyspnea and respiratory failure. 1 The …
characterized by airflow obstruction, worsening dyspnea and respiratory failure. 1 The …
No influence on cardiac arrhythmia or heart rate from long-term treatment with tiotropium/olodaterol versus monocomponents by holter ECG analysis in patients with …
S Andreas, U Bothner, A de la Hoz, I Kloer… - … Journal of Chronic …, 2020 - Taylor & Francis
Background Patients with chronic obstructive pulmonary disease (COPD) and
cardiovascular comorbidities may have an increased risk of medication-related cardiac …
cardiovascular comorbidities may have an increased risk of medication-related cardiac …
Asthma and COPD: A Focus on ẞ-Agonists–Past, Present and Future
JG Baker, DE Shaw - Adrenoceptors: 5 Selective α2 …, 2024 - books.google.com
Asthma has been recognised as a respiratory disorder for millennia and the focus of
targeted drug development for the last 120 years. Asthma is one of the most common …
targeted drug development for the last 120 years. Asthma is one of the most common …
Asthma and COPD: A Focus on β-Agonists–Past, Present and Future
JG Baker, DE Shaw - 2023 - Springer
Asthma has been recognised as a respiratory disorder for millennia and the focus of
targeted drug development for the last 120 years. Asthma is one of the most common …
targeted drug development for the last 120 years. Asthma is one of the most common …
Inhalative Therapie der COPD als Vulnerabilitätsfaktor hitzeassoziierter Exazerbationen: eine prospektive Studie im urbanen Berlin
AK Essler - 2023 - refubium.fu-berlin.de
Einleitung: Die Prävention von Exazerbationen ist ein wichtiges Therapieziel der COPD.
Dieses gewinnt durch den Klimawandel, mit zukünftig häufigeren Hitzewellen und …
Dieses gewinnt durch den Klimawandel, mit zukünftig häufigeren Hitzewellen und …
[PDF][PDF] Aus der Medizinischen Klinik mit Schwerpunkt Infektiologie und Pneumologie–Arbeitsbereich ambulante Pneumologie–der Medizinischen Fakultät Charité …
ITC als Vulnerabilitätsfaktor, AK Essler - core.ac.uk
Abstract Background: The prevention of Acute Exacerbations of Chronic Obstructive
Pulmonary Disease (AECOPD) remains an important goal of the pharmacologic therapy of …
Pulmonary Disease (AECOPD) remains an important goal of the pharmacologic therapy of …
[PDF][PDF] COPD und kardiovaskuläre Komorbiditäten: Interaktionen zwischen Lunge und Herz
P Alter, CF Vogelmeier, RA Jörres - medizin.mgo-fachverlage.de
COPD und kardiovaskuläre Komorbiditäten: Interaktionen zwischen Lunge und Herz Page 1
COPD und kardiovaskuläre Komorbiditäten: Interaktionen zwischen Lunge und Herz P. Alter …
COPD und kardiovaskuläre Komorbiditäten: Interaktionen zwischen Lunge und Herz P. Alter …